摘要
目的探讨卡培他滨和奥沙利铂(XELOX方案)联合小牛脾注射液治疗老年晚期胃癌的临床效果及对血清甲状腺转录因子-1(TTF-1)和肿瘤特异性生长因子(TSGF)水平的影响。方法选取2018年12月至2020年12月间郑州市第二人民医院收治的76例老年晚期胃癌患者,采用抛硬币法分为观察组和对照组,每组38例。对照组患者采用XELOX方案化疗,观察组患者采用XELOX方案联合小牛脾注射液治疗,比较两组患者治疗前后血清癌胚抗原(CEA)、糖类抗原125(CA125)、TTF-1和TSGF水平,分析患者临床疗效、生活质量、客观缓解率(ORR)、疾病控制率(DCR)、无进展生存时间(PFS)和不良反应。结果治疗后,两组患者TTF-1和TSGF水平均下降,且观察组下降幅度更大,差异均有统计学意义(均P<0.05)。治疗后,两组患者CEA和CA125水平均降低,且观察组下降更多,差异均有统计学意义(均P<0.05)。观察组患者ORR和DCR均高于对照组,差异均有统计学意义(均P<0.05)。两组患者治疗过程中均出现不同程度的不良反应,以Ⅰ~Ⅱ级胃肠道反应和骨髓抑制居多,经对症治疗后均得到缓解。观察组患者腹泻、恶心呕吐、白细胞下降和血小板下降情况均少于对照组,差异有统计学意义(P<0.05),两组患者肝功能异常和红细胞下降比较,差异无统计意义(P>0.05)。观察组患者PFS为8.4个月,高于对照组的6.7个月,差异有统计学意义(X^(2)=4.40,P=0.04)。观察组患者KPS评分提升率为94.7%,高于对照组的76.3%,差异有统计学意义(P<0.05)。结论XELOX方案联合小牛脾注射液治疗老年晚期胃癌患者,临床疗效确切,可降低血清TTF-1和TSGF水平,有效延长无进展生存时间,安全性较高,值得推广。
Objective To investigate the effect of capecitabine plus oxaliplatin(XELOX)regimen combined with calf extractive spleen injection in the treatment of elderly patients with advanced gastric cancer and its effects on serum thyroid transcription factor-1(TTF-1)and tumor specific growth factor(TSGF)levels.Methods Seven-six elderly patients with advanced gastric cancer admitted to Zhengzhou Second People’s Hospital from December 2018 to December 2020 were retrospectively analyzed.They were divided into an observation group and a control group by coin tossing method with 38 in each group.The observation group was treated with XELOX regimen combined with calf spleen extractive injection and the control group was treated with XELOX regimen alone.The levels of serum carcinoembryonic antigen(CEA),CA125,TTF-1 and TSGF were compared between the two groups before and after treatment.The clinical efficacy and improvement of quality of life objective response rate(ORR),disease control rate(DCR),progression-free survival(PFS)and anverse reactions were compared between the two groups(all P<0.05).Results After treatment,the serum levels of TTF-1,TSGF,CEA and CA125 in the two groups were significantly decreased,and the observation group had a greater decline than the control group.ORR and DCR were significantly higher in the observation group than in the control group(all P<0.05).Adverse reactions of various degree occurred in both groups and mostly were gradeⅠtoⅡgastrointestinal reactions and myelosuppression which were relieved after symptomatic treatment.The incidence of diarrhea,nausea and vomiting,neutropenia and thrombopenia was lower in the observation group than in the control group(all P<0.05).There was no significant difference in the incidence of hepatic dysfunction and erythrocytopenia between the two groups(P>0.05).PFS was 8.4 months in the observation group which was higher than 6.7 months in the control group(P<0.05).Karnofsky performance status score was improved by 94.7%which was higher than 76.3%of the contr
作者
刘朋卫
丁高峰
卢瑞杰
LIU Peng-wei;DING Gao-feng;LU Rui-jie(Department of Gastroenterology,Zhengzhou Second People’s Hospital,Zhengzhou 450006,China;Department of Oncology,Henan Cancer Hospital,Zhengzhou 450000,China;Department of Emergency,Yellow River Central Hospital,Zhengzhou 450000,China)
出处
《中国肿瘤临床与康复》
2021年第3期330-334,共5页
Chinese Journal of Clinical Oncology and Rehabilitation
关键词
卡培他滨
奥沙利铂
小牛脾注射液
胃肿瘤
甲状腺转录因子-1
肿瘤特异性生长因子
Capecitabine
Oxaliplatin
Calf spleen extractive injection
Advanced gastric neoplasms
Thyroid transcription factor-1
Tumor specific growth factor
